Combination Therapies Employing Ace Inhibitors and Uses Thereof for the Treatment of Diabetic Disorders

• US 20080139511A1
• Filed: 02/19/2008
• Published: 06/12/2008
• Est. Priority Date: 08/10/2004
• Status: Abandoned Application

• Current Assignee: Medicure International, Inc. (Medicure, Inc.)
• Original Assignee: Medicure International, Inc. (Medicure, Inc.)
• Inventors: Friesen, Albert D.
• Application Number:
  US12/033,392
• Publication Number:
  US 20080139511A1
• Time in Patent Office: Days
• US Class Current: 514/89
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/4415 Pyridoxine, i.e. Vitamin B6 pyridoxal phosphate A61K31/675
• CPC Class Codes: A61K 31/675 having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 9/12 Antihypertensives

Abstract

The present invention includes use of an angiotensin-converting enzyme (ACE) inhibitor in combination with a vitamin B6 related compound for the treatment of diabetes and diabetic related disorders and in particular the treatment of diabetic hypertension.

Claims

1. A method of treating or inhibiting hypertension in a diabetic patient comprising administering a therapeutically effective amount of an angiotensin converting enzyme (ACE) inhibitor and pyridoxal-5′

-phosphate, pharmaceutically acceptable acid addition salts thereof, or mixtures thereof, wherein the pyridoxal-5′

-phosphate is in a range of about 225 mg to about 500 mg per dose.

2. The method according to claim 1, wherein the ACE inhibitor is selected from a group consisting of benazepril, captopril, cilazapril, enalapril, enalaprilat, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, and a mixture thereof.

3. The method according to claim 1, wherein the ACE inhibitor is lisinopril and the therapeutically effective amount of lisinopril is between 5 and 40 mg per day.

4. The method according to claim 10, wherein the therapeutically effective amount of lisinopril is 20 mg per day.

5. The method according to claim 1, wherein the ACE inhibitor is captopril.

6. The method according to claim 1, wherein the ACE inhibitor is enalapril.

7. The method according to claim 1, wherein the ACE inhibitor is ramipril.

8. The method according to claim 1, wherein the ACE inhibitor is trandolapril.

9. The method according claim 1, wherein the diabetic patient is an insulin dependent diabetic patient.

10. The method according to claim 1, wherein the diabetic patient is a non-insulin dependent diabetic patient.

12. The method according to claim 1, wherein the ACE inhibitor is selected from a group consisting of benazepril, captopril, cilazapril, enalapril, enalaprilat, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, and a mixture thereof.

13. The method according to claim 1, wherein the ACE inhibitor is lisinopril and the therapeutically effective amount of lisinopril is between 5 and 40 mg per day.

14. The method according to claim 10, wherein the therapeutically effective amount of lisinopril is 20 mg per day.

15. The method according to claim 1, wherein the ACE inhibitor is captopril.

16. The method according to claim 1, wherein the ACE inhibitor is enalapril.

17. The method according to claim 1, wherein the ACE inhibitor is ramipril.

18. The method according to claim 1, wherein the ACE inhibitor is trandolapril.

19. The method according claim 1, wherein the diabetic patient is an insulin dependent diabetic patient.

20. The method according to claim 1, wherein the diabetic patient is a non-insulin dependent diabetic patient.

11. A method of controlling blood glucose or serum glucose in a diabetic patient comprising administering a therapeutically effective amount of an angiotensin converting enzyme (ACE) inhibitor and pyridoxal-5′

-phosphate, pharmaceutically acceptable acid addition salts thereof, or mixtures thereof, wherein the pyridoxal-5′

-phosphate is in a range of about 225 mg to about 500 mg per dose.